Aravive, Inc.

Less than three years after Mallinckrodt plc filed for bankruptcy protection to reorganize its finances in a manner that would allow for repayment of its debts and payouts under opioid litigation se

Genmab A/S is not going to advance an antibody-drug conjugate, enapotamab vedotin, into late-stage clinical development, citing stringent proof-of-concept criteria, thereby cementing the biotech’s la

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. LianBio Adds Pfizer To Initial Tie-Ups

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c